Alnylam Secures Positive CHMP Recommendation for Vutrisiran in Treating ATTR Amyloidosis with Cardiomyopathy In a significant regulatory milestone for RNA interference (RNAi) therapeutics, Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the industry…
Qualthera Health Launches R&D Subsidiary for Drug Repurposing and Novel Delivery Qualthera Pharmaceuticals Ltd. Co. aims to reshape the future of therapeutics through a patient-driven, data-informed approach to repurposing proven…
LEAP Boosts Digital Lab Transformation with Key Executive Appointment in Clinical Diagnostics LEAP Consulting Group, a renowned boutique digital consultancy specializing in guiding national clinical diagnostic laboratories through complex, multi-phase…
Contineum Therapeutics Names Timothy Watkins as CMO and Head of Development Contineum Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing innovative therapies for neuroscience, inflammation, and immunology (NI&I) disorders,…
IFF Pharma Solutions Set to Highlight Its Portfolio at Excipient World 2025 IFF Pharma Solutions, a division of International Flavors & Fragrances Inc. and a global leader in polymer innovation,…
Prilenia and Ferrer Partner on Pridopidine Commercialization and Development in Europe Prilenia Therapeutics B.V., a clinical-stage biopharmaceutical company dedicated to developing transformative therapies for neurodegenerative diseases, announced a significant new…
nChroma Bio to Present at ASGCT 2025 Annual Meeting nChroma Bio, an emerging leader in the field of genetic medicines, today announced the acceptance of three significant scientific abstracts at…
Revolution Medicines Shares Early Zoldonrasib Data in KRAS G12D NSCLC at 2025 AACR Revolution Medicines, Inc. a late-stage clinical oncology company committed to developing targeted therapies for patients with RAS-addicted…
Pfizer’s Sasanlimab Boosts Event-Free Survival in High-Risk NMIBC Pfizer Inc. (NYSE: PFE) announced today significant findings from its pivotal Phase 3 CREST trial evaluating sasanlimab, an investigational anti-PD-1 monoclonal antibody,…
KEYTRUDA Plus Standard Therapy Boosts Event-Free Survival in Resectable Head and Neck Cancer Merck , known as MSD outside the United States and Canada, has announced landmark findings from its…
UGN-102 Trials Show No Impact on Function, Symptoms, or QoL in LG-IR-NMIBC Patients UroGen Pharma Ltd. (Nasdaq: URGN), a biotechnology company focused on developing and commercializing innovative treatments for urothelial…
Gameto Launches First U.S. Clinical Site for Patient Enrollment in Fertilo Study Gameto, a clinical-stage biotechnology company at the forefront of developing cutting-edge iPSC (induced pluripotent stem cell)-based therapies to…